Head-To-Head Comparison: Chemed (CHE) vs. Its Rivals

Chemed (NYSE:CHE) is one of 235 public companies in the “Healthcare Providers & Services” industry, but how does it compare to its rivals? We will compare Chemed to related companies based on the strength of its earnings, dividends, analyst recommendations, profitability, risk, valuation and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Chemed and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0	5	2	0	2.29
Chemed Competitors	1811	7598	13041	797	2.55

Chemed presently has a consensus price target of $554.60, suggesting a potential upside of 8.14%. As a group, “Healthcare Providers & Services” companies have a potential upside of 15.72%. Given Chemed’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Chemed has less favorable growth aspects than its rivals.

Dividends

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. Chemed pays out 14.1% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.6% and pay out 25.4% of their earnings in the form of a dividend. Chemed has raised its dividend for 16 consecutive years.

Institutional & Insider Ownership

95.8% of Chemed shares are owned by institutional investors. Comparatively, 57.0% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 15.4% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Chemed and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Chemed	$2.53 billion	$265.24 million	25.76
Chemed Competitors	$20.63 billion	$281.74 million	-0.37

Chemed’s rivals have higher revenue and earnings than Chemed. Chemed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Chemed’s rivals have a beta of 0.98, indicating that their average share price is 2% less volatile than the S&P 500.

Profitability

This table compares Chemed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Chemed Competitors	-7.75%	-139.79%	-1.52%

Summary

Chemed rivals beat Chemed on 9 of the 15 factors compared.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.